PDP leader Madani allowed to travel to Kerala, stay there for treatment
New Delhi (PTI): The Supreme Court on Monday allowed People's Democratic Party (PDP) chairman Abdul Nasar Madani, a prime accused in the 2008 Bengaluru serial bomb blasts case, to travel to Kerala and stay there for treatment.
A bench of Justices A S Bopanna and M M Sundresh modified Madani's bail condition, which had directed him to stay in Bengaluru till the completion of his trial.
"In modification of the order dated July 11, 2014, we permit the applicant to travel to his hometown in Kerala and stay there. However, to ensure that the applicant is adhering to all other requirements, we direct that the appellant will report to the Station House Officer of the nearest police in Kollam district, once in 15 days. The charges for the same shall be borne by the applicant himself. It is open for the State of Karnataka to take all such precautions to ensure that the applicant does not abuse the liberty granted,” the bench said.
“Madani has been out on bail since 2014 after the Supreme Court granted relief in view of his poor health. But he was ordered not to leave Bengaluru. In April 2023, the apex court permitted him to visit Kerala to meet his ailing parents accompanied by the Karnataka Police escort and return in the same manner,” the High Court had said.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Ballari maternal deaths: Karnataka govt. seeks explanation from CDSCO
Bengaluru: The Karnataka Government has sought clarification from the Central drugs standard control organisation following reports linking the serial deaths of pregnant women at Ballari District Hospital to unsafe IV Ringer's Lactate solution. Health Department Principal Secretary Harsha Gupta has written a letter to the Drugs Controller General of India, Rajeev Singh Raghuvanshi.
Recent Investigations revealed bacterial and fungal contaminants in the IV solution given to the women. Out of 192 batches supplied by a West Bengal-based pharmaceutical company, 22 were found substandard by the state drug control department, leading to the suspension of the medicine's use.
However, these batches had passed quality tests at the Central Drug Lab, creating a regulatory conflict.
The Health Department emphasized adherence to tender rules, stating that the Central Drug Lab's approval is legally binding. Samples from the problematic batches have been sent for re-testing at the central lab in West Bengal, with results expected on December 9.
As a precautionary measure, the state has blacklisted the implicated batches and issued directives to halt their use in all hospitals.
